newsfilter
← Latest News
Business Wire·

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. (OTCQB:KRBP) ("Kiromic" or the "Company") reports good safety and favorable ongoing efficacy results from the 10-month follow-up visit of the first patient treated in its Deltacel-01 Phase 1